- Home
- NRGV vs GLUE Comparison
NRGV vs GLUE Comparison
Compare NRGV & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- GLUE
- Stock Information
- Founded
- NRGV 2017
- GLUE 2019
- Country
- NRGV United States
- GLUE United States
- Employees
- NRGV N/A
- GLUE N/A
- Industry
- NRGV Industrial Machinery/Components
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- NRGV Miscellaneous
- GLUE Health Care
- Exchange
- NRGV Nasdaq
- GLUE Nasdaq
- Market Cap
- NRGV 135.4M
- GLUE 390.3M
- IPO Year
- NRGV N/A
- GLUE 2021
- Fundamental
- Price
- NRGV $0.79
- GLUE $5.62
- Analyst Decision
- NRGV Hold
- GLUE Buy
- Analyst Count
- NRGV 5
- GLUE 4
- Target Price
- NRGV $2.25
- GLUE $13.75
- AVG Volume (30 Days)
- NRGV 387.5K
- GLUE 252.8K
- Earning Date
- NRGV 11-05-2024
- GLUE 11-07-2024
- Dividend Yield
- NRGV N/A
- GLUE N/A
- EPS Growth
- NRGV N/A
- GLUE N/A
- EPS
- NRGV N/A
- GLUE N/A
- Revenue
- NRGV $301,970,000.00
- GLUE $5,759,000.00
- Revenue This Year
- NRGV N/A
- GLUE N/A
- Revenue Next Year
- NRGV $544.38
- GLUE N/A
- P/E Ratio
- NRGV N/A
- GLUE N/A
- Revenue Growth
- NRGV 97.21
- GLUE N/A
- 52 Week Low
- NRGV $0.78
- GLUE $2.44
- 52 Week High
- NRGV $3.22
- GLUE $8.84
- Technical
- Relative Strength Index (RSI)
- NRGV 40.92
- GLUE 49.73
- Support Level
- NRGV $0.78
- GLUE $5.51
- Resistance Level
- NRGV $0.92
- GLUE $6.68
- Average True Range (ATR)
- NRGV 0.08
- GLUE 0.58
- MACD
- NRGV -0.01
- GLUE -0.09
- Stochastic Oscillator
- NRGV 4.79
- GLUE 11.18
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.